Gelatinase levels in male and female breast cancer

被引:27
作者
Giannelli, G
Fransvea, E
Marinosci, F
Bergamini, C
Daniele, A
Colucci, S
Paradiso, A
Quaranta, M
Antonaci, S
机构
[1] Univ Bari, Sch Med, Dept Internal Med Immunol & Infect Dis, Sect Internal Med, I-70124 Bari, Italy
[2] Univ Bari, Sch Med, Dept Human Anat & Histol, I-70124 Bari, Italy
[3] Inst Oncol, Lab Clin Diagnost, Bari, Italy
[4] Inst Oncol, Lab Clin Expt Oncol, Bari, Italy
关键词
male breast cancer; MMP-2; MMP-9; TIMP-2; gelatinases;
D O I
10.1006/bbrc.2002.6599
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer is a common disease in females but very rare in males, in whom it shows a more metastatic behavior, and a worse prognosis. Matrix metalloprotease-2 (MMP-2) and MMP-9 are proteolytic enzymes balanced by tissue inhibitor of MMP-2 (TIMP-2), commonly involved in cancer metastasis. This is the first study on gelatinolytic activity in male breast cancer patients, compared to that in female patients. In cancer tissues, both gelatinases were more expressed than in normal samples, being and more concentrated in male than in female patients. TIMP-2 levels were slightly increased in normal compared to those in cancer tissues and more concentrated in males than in females. Immunostaining showed that in male cancer tissues MMP-2 and MMP-9 staining was more intense and diffuse than in female cancer tissues, while no differences were observed regarding TIMP-2. In conclusion, the increased expression of gelatinases in male breast cancer patients together with anatomical features might explain the high tendency toward metastasis and the worse prognosis. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:161 / 166
页数:6
相关论文
共 29 条
[1]   Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells [J].
Abidi, SMA ;
Howard, EW ;
Dmytryk, JJ ;
Pento, JT .
CLINICAL & EXPERIMENTAL METASTASIS, 1997, 15 (04) :432-439
[2]  
BRACKE ME, 1994, CANCER RES, V54, P4607
[3]   Tissue inhibitors of metalloproteinases: evolution, structure and function [J].
Brew, K ;
Dinakarpandian, D ;
Nagase, H .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1477 (1-2) :267-283
[4]   Ongoing trials with matrix metalloproteinase inhibitors [J].
Brown, PD .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (09) :2167-2177
[5]   ACTIVITY OF TYPE-IV COLLAGENASES IN BENIGN AND MALIGNANT BREAST DISEASE [J].
DAVIES, B ;
MILES, DW ;
HAPPERFIELD, LC ;
NAYLOR, MS ;
BOBROW, LG ;
RUBENS, RD ;
BALKWILL, FR .
BRITISH JOURNAL OF CANCER, 1993, 67 (05) :1126-1131
[6]   Proteolysis in human breast and colorectal cancer [J].
Garbett, EA ;
Reed, MWR ;
Brown, NJ .
BRITISH JOURNAL OF CANCER, 1999, 81 (02) :287-293
[7]  
Garbisa S, 2001, CANCER-AM CANCER SOC, V91, P822, DOI 10.1002/1097-0142(20010215)91:4<822::AID-CNCR1070>3.0.CO
[8]  
2-G
[9]   Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma [J].
Giannelli, G ;
Bergamini, C ;
Marinosci, F ;
Fransvea, E ;
Quaranta, M ;
Lupo, L ;
Schiraldi, O ;
Antonaci, S .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (04) :425-431
[10]  
Giannelli G, 2002, HISTOL HISTOPATHOL, V17, P339, DOI 10.14670/HH-17.339